This article argues for the inclusion of whartons jelly in randomized controlled trials, emphasizing regulatory fairness and joint degeneration treatment improvement.
Key Points
Whartons jelly should be eligible for randomized controlled trials, enhancing treatment options for joint degeneration.
The study highlights the significant biological similarities between whartons jelly and platelet-rich plasma in regenerative therapy.
Regulatory exclusion of whartons jelly from homologous use appears inconsistent, given its reparative properties for cartilage matrix support.
Proposing whartons jelly as a homologous-use allograft could facilitate critical advances in non-operative care for millions.